On May 21, 2021, amivantamab, a bispecific antibody to EGFR and MET, was FDA approved for advanced NSCLC patients with EGFR exon 20 mutations after progression with chemotherapy. This evidence concerns the gene EGFR and non-small cell lung carcinoma.